GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Adcock Ingram Holdings Ltd (JSE:AIP) » Definitions » EBIT

Adcock Ingram Holdings (JSE:AIP) EBIT : R1,252 Mil (TTM As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Adcock Ingram Holdings EBIT?

Adcock Ingram Holdings's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was R650 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was R1,252 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Adcock Ingram Holdings's annualized ROC % for the quarter that ended in Dec. 2023 was 13.47%. Adcock Ingram Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 33.36%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Adcock Ingram Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 13.99%.


Adcock Ingram Holdings EBIT Historical Data

The historical data trend for Adcock Ingram Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adcock Ingram Holdings EBIT Chart

Adcock Ingram Holdings Annual Data
Trend Sep13 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 984.16 968.77 953.83 1,147.40 1,265.25

Adcock Ingram Holdings Semi-Annual Data
Mar14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 568.53 578.87 663.15 602.10 649.88

Competitive Comparison of Adcock Ingram Holdings's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Adcock Ingram Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adcock Ingram Holdings's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Adcock Ingram Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Adcock Ingram Holdings's EV-to-EBIT falls into.



Adcock Ingram Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was R1,252 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adcock Ingram Holdings  (JSE:AIP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Adcock Ingram Holdings's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=1177.452 * ( 1 - 26.64% )/( (6723.324 + 6102.618)/ 2 )
=863.7787872/6412.971
=13.47 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8262.534 - 1447.67 - ( 91.54 - max(0, 2434.209 - 4614.417+91.54))
=6723.324

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8329.023 - 2119.264 - ( 107.141 - max(0, 2444.775 - 4690.927+107.141))
=6102.618

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Adcock Ingram Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1299.754/( ( (1709.263 + max(2033.595, 0)) + (1689.321 + max(2359.551, 0)) )/ 2 )
=1299.754/( ( 3742.858 + 4048.872 )/ 2 )
=1299.754/3895.865
=33.36 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1848.746 + 2449.611 + 124.385) - (1447.67 + 0 + 941.477)
=2033.595

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2179.249 + 2404.537 + 0) - (2119.264 + 0 + 104.971)
=2359.551

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Adcock Ingram Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=1251.977/8948.183
=13.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adcock Ingram Holdings EBIT Related Terms

Thank you for viewing the detailed overview of Adcock Ingram Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Adcock Ingram Holdings (JSE:AIP) Business Description

Traded in Other Exchanges
N/A
Address
1 New Road, (c/o New Road & 7th Street), Midrand, Johannesburg, GT, ZAF, 1682
Adcock Ingram Holdings Ltd is a drug manufacturing company. The company manufactures, markets, and distributes a wide range of healthcare products. The company generates roughly two-thirds of its sales from the private sector, with the remaining from the public sector. Adcock operates in four broad areas: renal disease, medicine delivery, transfusion therapies, and blood and specialized pharmaceuticals. The company generates the vast majority of its revenue in southern Africa, followed by the rest of Africa and India.